European Commission approves new Nova Xaluprine oral formulation
Supplied from January 2013, revised formulation is indicated for acute lymphoblastic leukaemia and is free from artificial colours, artificial flavours and sugar. According to the company, the medication
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.